We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.
Company Details
- Founded
- 2020
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.april19.ai
- Keywords
- AI, psychedelics, biotech, machine learning, drug discovery, drug design, startup, GenerativeAI, psychoplastogens, neurodegeneration, traumatic brain injury, healthspan, mental healthspan, longevity, neuroplasticity, Seed-stage, pharmaceuticals, pharma, research, neurorestoration, neuroprotection, healthcare, venture.
- HQ
- London
April19 Discovery Questions
April19 Discovery's website is https://www.april19.ai
April19 Discovery's LinkedIn profile is https://uk.linkedin.com/company/april19ai
April19 Discovery's industry is
Biotechnology Research
April19 Discovery's top competitors are
Aimble,
Salina Health Ltd,
Gtn Bioconsulting,
Pivox Health,
Insidedna,
Zebraml,
Tzager,
Galixir,
Ailynix,
Spannr - Your Gateway To Longevity.
April19 Discovery's categories are Biotechnology Research
April19 Discovery's founding year is 2020
